Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation
Serena Yun‐Chen Tsai(Harvard University), Kevin Sheng‐Kai(Harvard University), Ashwin N. Ananthakrishnan(Harvard University), Harland S. Winter(Massachusetts General Hospital)
Cited by 1
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
Environmental triggers in IBD: a review of progress and evidence
|Nature Reviews Gastroenterology & Hepatology|2017|931